114 related articles for article (PubMed ID: 3087399)
1. Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity.
Judson IR; Rutty CJ; Abel G; Graham MA
Br J Cancer; 1986 May; 53(5):601-6. PubMed ID: 3087399
[TBL] [Abstract][Full Text] [Related]
2. Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.
Rutty CJ; Judson IR; Abel G; Goddard PM; Newell DR; Harrap KR
Cancer Chemother Pharmacol; 1986; 17(3):251-8. PubMed ID: 3091280
[TBL] [Abstract][Full Text] [Related]
3. The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.
Rutty CJ; Newell DR; Muindi JR; Harrap KR
Cancer Chemother Pharmacol; 1982; 8(1):105-11. PubMed ID: 6807560
[TBL] [Abstract][Full Text] [Related]
4. Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.
Broggini M; Rossi C; Colombo T; D'Incalci M
Cancer Treat Rep; 1982 Jan; 66(1):127-33. PubMed ID: 6796267
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of hexamethylmelamine and pentamethylmelamine in mice.
Broggini M; Colombo T; D'Incalci M; Donnelli MG; Gescher A; Garattini S
Cancer Treat Rep; 1981; 65(7-8):669-72. PubMed ID: 6788370
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
Judson IR; Calvert AH; Rutty CJ; Abel G; Gumbrell LA; Graham MA; Evans BD; Wilman DE; Ashley SE; Cairnduff F
Cancer Res; 1989 Oct; 49(19):5475-9. PubMed ID: 2670205
[TBL] [Abstract][Full Text] [Related]
7. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.
Boven E; Nauta MM; Schlüper HM; Erkelens CA; Pinedo HM
Cancer Chemother Pharmacol; 1986; 18(2):124-8. PubMed ID: 3098444
[TBL] [Abstract][Full Text] [Related]
8. N2,N4,N6-tri(hydroxymethyl)-N2,N4,N6-trimethylmelamine (trimelamol) is an efficient DNA cross-linking agent in vitro.
Jackson C; Hartley JA; Jenkins TC; Godfrey R; Saunders R; Thurston DE
Biochem Pharmacol; 1991 Nov; 42(11):2091-7. PubMed ID: 1958227
[TBL] [Abstract][Full Text] [Related]
9. First-pass metabolism of pentamethylmelamine in the rat liver.
Klippert PJ; Hulshoff A; Hofman GA; Noordhoek J
Cancer Res; 1985 Mar; 45(3):983-6. PubMed ID: 3918792
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of pentamethylmelamine in humans.
Benvenuto JA; Stewart DJ; Benjamin RS; Loo TL
Cancer Res; 1981 Feb; 41(2):566-9. PubMed ID: 6778609
[TBL] [Abstract][Full Text] [Related]
11. Studies on the stability of trimelamol, a carbinolamine-containing antitumor drug.
Jackson C; Crabb TA; Gibson M; Godfrey R; Saunders R; Thurston DE
J Pharm Sci; 1991 Mar; 80(3):245-51. PubMed ID: 2051341
[TBL] [Abstract][Full Text] [Related]
12. Human central nervous system pharmacology of pentamethylmelamine and its metabolites.
Stewart DJ; Benvenuto JA; Leavens M; Smith RG; Cabanillas F; Benjamin RS; Loo TL
J Neurooncol; 1983; 1(4):357-64. PubMed ID: 6432969
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent pharmacokinetics of PMM in the rat.
Colombo T; Torti L; D'Incalci M
Cancer Chemother Pharmacol; 1981; 5(3):201-3. PubMed ID: 6794923
[TBL] [Abstract][Full Text] [Related]
14. N-(Hydroxymethyl) melamines.
Coley HM
Gen Pharmacol; 1997 Feb; 28(2):177-82. PubMed ID: 9013191
[TBL] [Abstract][Full Text] [Related]
15. Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies.
Muindi JR; Newell DR; Smith IE; Harrap KR
Br J Cancer; 1983 Jan; 47(1):27-33. PubMed ID: 6401427
[TBL] [Abstract][Full Text] [Related]
16. Biochemical studies on the ability of pentamethylmelamine to interact in vivo with DNA and proteins in a sensitive murine ovarian reticular cell sarcoma.
Garattini E; Broggini M; Coccia P; Colombo T; Rossi C; D'Incalci M
Biochem Pharmacol; 1984 Sep; 33(17):2715-22. PubMed ID: 6431992
[TBL] [Abstract][Full Text] [Related]
17. A sensitive and specific assay for pentamethylmelamine in plasma: applicability to clinical studies.
Dutcher JS; Jones RB; Boyd MR
Cancer Treat Rep; 1980 Jan; 64(1):99-104. PubMed ID: 6769585
[TBL] [Abstract][Full Text] [Related]
18. Specific determination of pentamethylmelamine and its demethylated metabolites in human plasma by high pressure liquid chromatography.
Leyland-Jones BR; Deesen PE; Casper ES; Young CW
Ther Drug Monit; 1982; 4(2):185-90. PubMed ID: 6808715
[TBL] [Abstract][Full Text] [Related]
19. Studies of the mode of action of antitumour triazenes and triazines-V. The correlation of the in vitro cytotoxicity and in vivo antitumour activity of hexamethylmelamine analogues with their metabolism.
Ross D; Langdon SP; Gescher A; Stevens MF
Biochem Pharmacol; 1984 Apr; 33(7):1131-6. PubMed ID: 6424683
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of trimelamol against human breast carcinoma xenografts in nude mice.
Yamada Y; Kubota T; Hoshiya Y; Asanuma F; Koh J; Kitajima M; Coley H; Judson I
Oncol Rep; 1996 Jul; 3(4):613-7. PubMed ID: 21594422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
